Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

被引：25

作者：

Brooimans, Rik A. ^{[1
,2
]}

van der Velden, Vincent H. J. ^{[1
]}

Boeckx, Nancy ^{[3
]}

Slomp, Jennita ^{[4
]}

Preijers, Frank ^{[5
]}

te Marvelde, Jeroen G. ^{[1
]}

Van, Ngoc M. ^{[2
]}

Heijs, Antoinette ^{[4
]}

Huys, Erik ^{[5
]}

van der Holt, Bronno ^{[6
]}

de Greef, Georgine E. ^{[6
]}

Kelder, Angele ^{[7
]}

Schuurhuis, Gerrit Jan ^{[7
]}

机构：

[1] Univ Med Ctr Rotterdam, Erasmus MC, Lab Med Immunol, Dept Immunol, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands

[2] Univ Med Ctr Rotterdam, Erasmus MC, Lab Clin & Tumor Immunol, Rotterdam, Netherlands

[3] Univ Leuven, Lab Expt Transplantat, Leuven, Belgium

[4] Med Spectrum Twente Medlon, Dept Clin Chem, Enschede, Netherlands

[5] Radboud UMC, Hematol Lab, Dept Lab Med, Nijmegen, Netherlands

[6] Univ Med Ctr Rotterdam, Dept Hematol, Erasmus MC, Rotterdam, Netherlands

[7] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

来源：

LEUKEMIA RESEARCH | 2019年 / 76卷

关键词：

AML; Measurable residual disease; Flow cytometry; Multicentre; MULTIPARAMETER FLOW-CYTOMETRY; ABERRANT PHENOTYPES; UNSELECTED PATIENTS; HIGH-FREQUENCY; AML; THERAPY; RELAPSE; STANDARDIZATION; RELEVANCE; DIAGNOSIS;

D O I：

10.1016/j.leukres.2018.11.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Flow-cytometric detection of now termed measurable residual disease (MRD) in acute myeloid leukemia (AML) has proven to have an independent prognostic impact. In a previous multicenter study we developed protocols to accurately define leukemia-associated immunophenotypes (LAIPs) at diagnosis. It has, however, not been demonstrated whether the use of the defined LAIPs in the same multicenter setting results in a high concordance between centers in MRD assessment. In the present paper we evaluated whether interpretation of list-mode data (LMD) files, obtained from MRD assessment of previously determined LAIPs during and after treatment, could reliably be performed in a multicenter setting. The percentage of MRD positive cells was simultaneously determined in totally 173 LMD files from 77 AML patients by six participating centers. The quantitative concordance between the six participating centers was meanly 84%, with slight variation of 75%-89%. In addition our data showed that the type and number of LAIPs were of influence on the performance outcome. The highest concordance was observed for LAIPs with cross-lineage expression, followed by LAIPs with an asynchronous antigen expression. Our results imply that immunophenotypic MRD assessment in AML will only be feasible when fully standardized methods are used for reliable multicenter assessment.

引用

页码：39 / 47

页数：9

共 44 条

[11] MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia [J].

Feller, N ;

van der Pol, MA ;

van Stijn, A ;

Weijers, GWD ;

Westra, AH ;

Evertse, BW ;

Ossenkoppele, GJ ;

Schuurhuis, GJ .

LEUKEMIA, 2004, 18 (08) :1380-1390

[12] Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting [J].

Feller, N. ;

van der Velden, V. H. J. ;

Brooimans, R. A. ;

Boeckx, N. ;

Preijers, F. ;

Kelder, A. ;

de Greef, I. ;

Westra, G. ;

te Marvelde, J. G. ;

Aerts, P. ;

Wind, H. ;

Leenders, M. ;

Gratama, J. W. ;

Schuurhuis, G. J. .

BLOOD CANCER JOURNAL, 2013, 3 :e129-e129

[13] Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma [J].

Flores-Montero, J. ;

Sanoja-Flores, L. ;

Paiva, B. ;

Puig, N. ;

Garcia-Sanchez, O. ;

Boettcher, S. ;

van der Velden, V. H. J. ;

Perez-Moran, J-J ;

Vidriales, M-B ;

Garcia-Sanz, R. ;

Jimenez, C. ;

Gonzalez, M. ;

Martinez-Lopez, J. ;

Corral-Mateos, A. ;

Grigore, G-E ;

Fluxa, R. ;

Pontes, R. ;

Caetano, J. ;

Sedek, L. ;

del Canizo, M-C ;

Blade, J. ;

Lahuerta, J-J ;

Aguilar, C. ;

Barez, A. ;

Garcia-Mateo, A. ;

Labrador, J. ;

Leoz, P. ;

Aguilera-Sanz, C. ;

San-Miguel, J. ;

Mateos, M-V ;

Durie, B. ;

van Dongen, J. J. M. ;

Orfao, A. .

LEUKEMIA, 2017, 31 (10) :2094-2103

[14] Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia [J].

Freeman, Sylvie D. ;

Virgo, Paul ;

Couzens, Steve ;

Grimwade, David ;

Russell, Nigel ;

Hills, Robert K. ;

Burnett, Alan K. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4123-+

[15]

Grimwade D, 2014, BLOOD, V124, P3345, DOI [10.1182/blood-2014-05-577593, 10.1182/asheducation-2014.1.222]

[16] Assessment of minimal residual disease in acute myeloid leukemia [J].

Grimwade, David ;

Vyas, Paresh ;

Freeman, Sylvie .

CURRENT OPINION IN ONCOLOGY, 2010, 22 (06) :656-663

[17] When the Minimal Becomes Measurable [J].

Hourigan, Christopher S. ;

Goswami, Meghali ;

Battiwalla, Minoo ;

Barrett, Austin J. ;

Sheela, Sheenu ;

Karp, Judith E. ;

Lai, Catherine .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) :2557-+

[18] Molecular Minimal Residual Disease in Acute Myeloid Leukemia [J].

Jongen-Lavrencic, M. ;

Grob, T. ;

Hanekamp, D. ;

Kavelaars, F. G. ;

al Hinai, A. ;

Zeilemaker, A. ;

Erpelinck-Verschueren, C. A. J. ;

Gradowska, P. L. ;

Meijer, R. ;

Cloos, J. ;

Biemond, B. J. ;

Graux, C. ;

Kooy, M. van Marwijk ;

Manz, M. G. ;

Pabst, T. ;

Passweg, J. R. ;

Havelange, V. ;

Ossenkoppele, G. J. ;

Sanders, M. A. ;

Schuurhuis, G. J. ;

Lowenberg, B. ;

Valk, P. J. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) :1189-1199

[19] EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols [J].

Kalina, T. ;

Flores-Montero, J. ;

van der Velden, V. H. J. ;

Martin-Ayuso, M. ;

Boettcher, S. ;

Ritgen, M. ;

Almeida, J. ;

Lhermitte, L. ;

Asnafi, V. ;

Mendonca, A. ;

de Tute, R. ;

Cullen, M. ;

Sedek, L. ;

Vidriales, M. B. ;

Perez, J. J. ;

te Marvelde, J. G. ;

Mejstrikova, E. ;

Hrusak, O. ;

Szczepanski, T. ;

van Dongen, J. J. M. ;

Orfao, A. .

LEUKEMIA, 2012, 26 (09) :1986-2010

[20] Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia [J].

Kern, W ;

Voskova, D ;

Schoch, C ;

Hiddemann, W ;

Schnittger, S ;

Haferlach, T .

BLOOD, 2004, 104 (10) :3078-3085

← 1 2 3 4 5 →